Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in January 2012 on request of the Sponsor.
On 5 September 2008, orphan designation (EU/3/08/560) was granted by the European Commission to KeyNeurotek Pharmaceuticals AG, Germany, for (-)-(2R)-3-(2-hydroxymethylindanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate for the treatment of moderate and severe closed traumatic brain injury.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
EU/3/08/560: Public summary of positive opinion for orphan designation of (-)-(2R)-3-(2-hydroxymethylindanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate for the treatment of moderate and severe closed traumatic brai... (PDF/127.64 KB)
First published: 24/04/2009
Last updated: 28/11/2013
|Disease / condition||
Treatment of moderate and severe closed traumatic brain injury
|Date of decision||
|Orphan decision number||
Sponsor's contact details
Tel. + 49 391 6117 220
Gax: + 49 391 6117 221
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.